Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
$4.37
$4.92
$2.60
$11.99
$4.24M1.5526,396 shs35,704 shs
Biocept, Inc. stock logo
BIOC
Biocept
$0.97
$0.32
$27.00
$1.14M0.69764,067 shs751,400 shs
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
$15.67
+2.9%
$17.69
$4.66
$34.05
$61.24M1.66134,027 shs396,663 shs
OpGen, Inc. stock logo
OPGN
OpGen
$5.02
+6.1%
$4.83
$0.53
$5.25
$50.54M-1.669,289 shs10,479 shs
Psychemedics Corporation stock logo
PMD
Psychemedics
$2.67
$2.52
$1.50
$3.25
$16.31MN/A35,163 shs113,627 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
0.00%0.00%0.00%0.00%0.00%
Biocept, Inc. stock logo
BIOC
Biocept
0.00%0.00%0.00%0.00%0.00%
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
0.00%+9.35%+10.04%+30.69%+27.19%
OpGen, Inc. stock logo
OPGN
OpGen
0.00%+0.64%+0.64%+35.53%+77.15%
Psychemedics Corporation stock logo
PMD
Psychemedics
0.00%0.00%0.00%0.00%+9.88%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
N/AN/AN/AN/AN/AN/AN/AN/A
Biocept, Inc. stock logo
BIOC
Biocept
N/AN/AN/AN/AN/AN/AN/AN/A
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/AN/AN/AN/A
Psychemedics Corporation stock logo
PMD
Psychemedics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
0.00
N/AN/AN/A
Biocept, Inc. stock logo
BIOC
Biocept
0.00
N/AN/AN/A
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
0.00
N/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
0.00
N/AN/AN/A
Psychemedics Corporation stock logo
PMD
Psychemedics
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
$1.75M2.42N/AN/A($1.41) per share-3.10
Biocept, Inc. stock logo
BIOC
Biocept
$25.86M0.00N/AN/A$15.60 per share0.00
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
$4.46M13.73N/AN/A$6.78 per share2.31
OpGen, Inc. stock logo
OPGN
OpGen
$2.67M18.91N/AN/A($11.55) per share-0.43
Psychemedics Corporation stock logo
PMD
Psychemedics
$19.68M0.83N/AN/A$0.84 per share3.18
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
-$14.77MN/A0.00N/AN/AN/AN/AN/A
Biocept, Inc. stock logo
BIOC
Biocept
-$32.09M-$58.45N/AN/AN/AN/A-468.87%-118.41%N/A
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
-$41.87M-$20.09N/AN/AN/A-1,393.50%-141.66%-88.74%N/A
OpGen, Inc. stock logo
OPGN
OpGen
-$32.67MN/A0.00N/A-1,140.36%N/A-287.58%7/7/2025 (Estimated)
Psychemedics Corporation stock logo
PMD
Psychemedics
-$1.86M-$0.51N/AN/A-9.26%-32.32%-18.53%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
N/AN/AN/AN/AN/A
Biocept, Inc. stock logo
BIOC
Biocept
N/AN/AN/AN/AN/A
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
N/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/A
Psychemedics Corporation stock logo
PMD
Psychemedics
N/AN/AN/AN/A1 Years
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
N/A
0.32
0.32
Biocept, Inc. stock logo
BIOC
Biocept
2.88
1.81
1.70
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
0.20
4.23
4.23
OpGen, Inc. stock logo
OPGN
OpGen
N/A
5.45
5.45
Psychemedics Corporation stock logo
PMD
Psychemedics
0.01
1.82
1.82

Institutional Ownership

CompanyInstitutional Ownership
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
45.84%
Biocept, Inc. stock logo
BIOC
Biocept
N/A
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
N/A
OpGen, Inc. stock logo
OPGN
OpGen
2.68%
Psychemedics Corporation stock logo
PMD
Psychemedics
32.07%

Insider Ownership

CompanyInsider Ownership
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
26.22%
Biocept, Inc. stock logo
BIOC
Biocept
1.61%
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
1.10%
OpGen, Inc. stock logo
OPGN
OpGen
43.80%
Psychemedics Corporation stock logo
PMD
Psychemedics
13.96%
CompanyEmployeesShares OutstandingFree FloatOptionable
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
86970,000715,000Not Optionable
Biocept, Inc. stock logo
BIOC
Biocept
502.63 million2.58 millionNot Optionable
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
453.91 millionN/ANot Optionable
OpGen, Inc. stock logo
OPGN
OpGen
10010.07 million4.70 millionNot Optionable
Psychemedics Corporation stock logo
PMD
Psychemedics
1406.11 million5.26 millionNot Optionable

Recent News About These Companies

Psychemedics Releases 2025 Workforce Insights Report
Phoenix Molecular Designs Launches Phase II Trial in RSK2-High Breast Cancer
Psychemedics announces reverse stock split, forward stock split
Psychemedics reminds stockholders to cast votes for Annual Meeting
Psychemedics Reports Improved Losses Amid Revenue Dip
Psychemedics Corporation (PMD)

Media Sentiment Over Time

Fresh2 Group stock logo

Fresh2 Group NASDAQ:ANPC

AnPac Bio-Medical Science Co., Ltd., a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup package services. The company was incorporated in 2010 and is headquartered in Lishui, the People's Republic of China.

Biocept stock logo

Biocept NASDAQ:BIOC

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Miragen Therapeutics stock logo

Miragen Therapeutics NASDAQ:MGEN

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.

OpGen stock logo

OpGen NASDAQ:OPGN

$5.02 +0.29 (+6.13%)
As of 03:37 PM Eastern

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

Psychemedics stock logo

Psychemedics NASDAQ:PMD

Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. The company's testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. It offers its services to employers for job applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. The company was incorporated in 1986 and is headquartered in Dallas, Texas.